# Effect of Danazol on Endometrial αvβ3 Integrin Expression in Patients With Unexplained Recurrent Implantation Failure

> **NCT03563664** · PHASE3 · COMPLETED · sponsor: **Ain Shams University** · enrollment: 38 (actual)

## Conditions studied

- Unexplained Infertility

## Interventions

- **PROCEDURE:** Pre-treatment endometrial biopsy
- **DRUG:** Danazol
- **PROCEDURE:** Post-treatment endometrial biopsy

## Key facts

- **NCT ID:** NCT03563664
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-01
- **Primary completion:** 2017-08-15
- **Final completion:** 2017-08-15
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03563664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03563664, "Effect of Danazol on Endometrial αvβ3 Integrin Expression in Patients With Unexplained Recurrent Implantation Failure". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03563664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*